GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Total Inventories

Horizon Therapeutics (Horizon Therapeutics) Total Inventories : $170 Mil (As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Total Inventories?

Horizon Therapeutics's total inventories for the quarter that ended in Jun. 2023 was $170 Mil. Horizon Therapeutics's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $167 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Horizon Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-3.79.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Horizon Therapeutics's Days Inventory for the three months ended in Jun. 2023 was 69.45.

Inventory Turnover measures how fast the company turns over its inventory within a year. Horizon Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 was 1.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Horizon Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.18.


Horizon Therapeutics Total Inventories Historical Data

The historical data trend for Horizon Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Total Inventories Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.75 53.80 75.28 225.73 169.56

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.68 190.26 169.56 164.50 170.33

Horizon Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Horizon Therapeutics  (NAS:HZNP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Horizon Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

Net-Net Working Capital Per Share (Q: Jun. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2496.513+0.75 * 717.417+0.5 * 170.325-3987.782
-0-0)/228.939
=-3.79

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Horizon Therapeutics's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=167.4105/219.958*365 / 4
=69.45

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Horizon Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=219.958 / 167.4105
=1.31

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Horizon Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=167.4105 / 944.959
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Horizon Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000